We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Attempt to Remove Thorium by Use of Chelating Agent

Roger J. Fontaine, MD; Doris E. Barber, MD; Constantine J. Maletskos, PhD; Edward W. Webster, PhD; John R. Graham, MD
JAMA. 1963;184(1):55. doi:10.1001/jama.1963.73700140008018.
Text Size: A A A
Published online


COLLOIDAL thorium dioxide (Thorotrast) was used extensively from 1928 until about 1950 to perform arteriograms, urograms, fistulagrams, and to outline focal lesions of the liver. The radiation dose from the amount usually injected is sufficient to warrant the expectation that neoplasms might develop in tissues chronically exposed to this agent which is almost totally retained in the body and remains radioactive for many years.

The first example of a malignant tumor in man induced by thorium dioxide was reported in 1947.1 By March of 1962, 55 well-documented examples of Thorotrast-induced malignancy in man had been reported.2-8

Recently, chelating agents have been found useful in removing heavy metals from humans. Animal and human experiments9-11 suggest that diethylenetriaminepentacetic acid (DTPA) may be effective in the removal of thorium, although there are indications that the ionic form of thorium would be more susceptible than the colloidal form.

Materials and 


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.